Versant Ventures related stories
All articles and analysis
Versant Ventures targets $350 mln for sixth fundVersant Ventures is seeking to raise $350 million for its sixth fund, according to an SEC filing https://www.sec.gov/Archives/edgar/data/1689067/000168788016000001/xslFormDX01/primary_doc.xml In 2015, the healthcare-focused investment firm closed its http://www.versantventures.com//wp-content/uploads/2014/12/Versant-V-Press-Release_US_Dec-10th_FINAL-11.pdf fifth fund at $305 million.
Turnstone Biologics raises $55.3 mln in OrbiMed-led Series BTurnstone Biologics Inc, an Ottawa developer of novel oncolytic viral immunotherapies for cancer, has secured about $55.3 million (US$41.4 million) in a Series B financing. The round was led by OrbiMed, a U.S. venture capital firm. It was joined by F-Prime Capital Partners and existing investors FACIT and Versant Ventures, which led Turnstone’s $11.3 million Series A round /canada/2015/10/turnstone-rakes-in-11-3-mln-series-a-in-versant-led-round-2/ in late 2015. As a result, Rishi Gupta of OrbiMed and Ben Auspitz of F-Prime will join the company's board. Turnstone was founded in 2014 based on Canadian scientific research. It plans to use the funds raised to complete an initial clinical trial, and for additional programs that will start this year and next.
- Turnstone Biologics scores $41.4 mln Series B
Canada-based Turnstone Biologics Inc, a developer of new oncolytic viral immunotherapies, has closed $41.4 million Series B financing. OrbiMed led the round with participation from F-Prime Capital Partners, FACIT and Versant Ventures.
- 5AM adds principal, venture partner and CFO to staff
5AM Ventures Management LLC has expanded its team with three new additions. Joining the firm are Dr. David Allison as principal, Joe Victor as venture partner and Rebecca Lucia as chief financial officer. Previously, Allison was a principal at Versant Ventures while Lucia was chief financial officer at Prospect Venture Partners. Victor is the former CEO of 5AM portfolio companies DVS Sciences (which was acquired by Fluidigm) and Startide Sciences.
- VC-backed Audentes debuts IPO
San Francisco-based Audentes Therapeutics, a developer of gene therapy products for patients with serious, life-threatening rare diseases, has raised $75 million for its IPO after pricing its 5 million shares at $15 per share. The stock began trading July 20, 2016 on the NASDAQ under the ticker symbol "BOLD." BofA Merrill Lynch, Cowen and Company and Piper Jaffray are serving as the lead underwriters. Audentes' backers included Deerfield Management, Sofinnova Ventures, Venrock, OrbiMed, 5AM Ventures and Versant Ventures.
- VC-backed Aprea appoints new president/CEO
Sweden and Boston-based biopharmaceutical development company Aprea AB has named Christian S. Schade as president and CEO. Previously, Schade was CEO of Novira Therapeutics. Aprea's backers include Versant Ventures, 5AM Ventures, Sectoral Asset Management and HealthCap.
Data spotlight: Sale of Vantage Oncology leads VC-backed M&A in AprilSeven of the April acquisitions disclosed financials terms, which combined to about $3.3 billion in value
VCs on the Move Apr 25, 2016Summary of recent moves at General Catalyst and other venture firms
- J&J subsidiary acquires HIG-backed NeuWave Medical
Medical device maker NeuWave Medical Inc has been acquired by Johnson & Johnson subsidiary Ethicon, according to an announcment by HIG BioHealth Partners, an investor in NeuWave. Terms of the deal were not disclosed. NeuWave, based in Madison, Wisconsin, had previously raised $44.5 million over four rounds, CrunchBase reported. Most recently, NeuWave pulled in a $25 million Series C round in May 2015 led by Versant Ventures with participation from HIG, the State of Wisconsin Investment Board, and Venture Investors.